This marks the second transaction between Harrow and Novartis.
It's the second FDA-approved indication for the drug.
The 3-year relationship will support effective policy dialogue, planning and implementation of eye health services in the region.
Vedere Bio's targets include inherited retinal dystrophies.
The agreements relate to violations in Greece, Vietnam and South Korea.
It will continue developing the company's technology.
9 of the latest products available and how to educate patients about them.
The goal was to help diabetes patients.
The eyecare business will be a standalone company. Novartis announced that it will spin off Alcon, its eyecare division, into a separately traded standalone company. The...
The firm is working on a treatment for diabetic macular edema. LAUSANNE, SWITZERLAND — Oculis, a biotechnology company focused on eye drops, has closed a $20.3...
The site beat out 2 non-US locations. Alcon will invest $97 million to expand production capacity at a plant near Atlanta. The project at the Johns Creek...
He’ll start on June 1. (Press Release) FORT WORTH, TX – Alcon, a division of Novartis, has appointed Dr. Stephen S. Lane as chief medical officer and...
The deal closed Jan. 20. Novartis paid $465 million for Encore Vision Inc., a privately held company in Fort Worth, TX, reports DallasNews.com. The acqusition was...
Alcon’s sales fell 3 percent in 2016. The CEO of Novartis said the company continues to mull the possibility of spinning off its Alcon eyecare unit....
It’s a “potentially disruptive innovation,” Novartis says. Novartis plans to acquire Encore Vision Inc., a privately held company in Fort Worth, TX, focused on the development...
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
Tons of business ideas for eyecare professionals!
Advertisement
